Table 3.

Outcomes among women and men in JUPITER

	Rosuvastatin Women N=3,426 Men N=5,475		Placebo Women N=3,375 Men N=5,526		Hazard Ratio (95% CI)	P	P for Heterogeneity
	No.	Rate per 100 p-y	No.	Rate per 100 p-y
Women
Primary endpoint	39	0.56	70	1.04	0.54 (0.37–0.80)	0.002	0.80
Nonfatal MI	8	0.12	14	0.21	0.56 (0.24–1.33)	0.18	0.24
Any MI	10	0.14	18	0.27	0.54 (0.25–1.18)	0.11	0.60
Nonfatal stroke	18	0.26	21	0.31	0.84 (0.45–1.58)	0.59	0.04
Any stroke	18	0.26	23	0.34	0.77 (0.42–1.42)	0.40	0.09
Arterial revascularization	8	0.12	29	0.43	0.27 (0.12–0.59)	0.0003	0.04
Arterial revascularization or hospitalization for unstable angina	8	0.12	33	0.49	0.24 (0.11–0.51)	<0.0001	0.01
MI, stroke, or confirmed death from cardiovascular causes	36	0.52	48	0.71	0.73 (0.48–1.13)	0.16	0.06
Venous thromboembolism	12	0.17	16	0.24	0.74 (0.35–1.55)	0.42	0.43
Death from any cause
Death on known date	57	0.78	69	0.95	0.81 (0.57–1.16)	0.25	0.99
Any death	60	0.82	77	1.07	0.77 (0.55–1.06)	0.12	0.74
Men
Primary endpoint	103	0.88	181	1.54	0.58 (0.45–0.73)	<0.0001
Nonfatal MI	14	0.12	48	0.40	0.29 (0.16–0.54)	<0.0001
Any MI	21	0.18	50	0.42	0.42 (0.26–0.71)	0.0006
Nonfatal stroke	12	0.10	37	0.31	0.33 (0.17–0.63)	0.0003
Any stroke	15	0.13	41	0.34	0.37 (0.21–0.67)	0.0005
Arterial revascularization	63	0.54	102	0.86	0.63 (0.46–0.86)	0.003
Arterial revascularization or hospitalization for unstable angina	68	0.58	110	0.93	0.63 (0.46–0.85)	0.002
MI, stroke, or confirmed death from cardiovascular causes	47	0.40	109	0.92	0.44 (0.31–0.61)	<0.0001
Venous thromboembolism	22	0.19	44	0.37	0.51 (0.30–0.85)	0.008
Death from any cause
Death on known date	133	1.07	166	1.32	0.81 (0.65–1.02)	0.07
Any death	138	1.11	170	1.35	0.82 (0.66–1.03)	0.08

MI: myocardial infarction. P for heterogeneity of treatment effect for outcomes between women and men were obtained from likelihood ratio tests that included treatment assignment, sex, and the interaction term.